Please assess the completion status of the following clinical trial:

Trial Title: Almorexant in Primary Insomnia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women 18 - 65 years of age (inclusive).~* Women of childbearing potential must have a negative urine pregnancy test at the screening visit, the screening adaptation night, and pre-treatment and use a reliable method of contraception during the entire study duration and for at least 3 months after study drug intake.~Reliable methods of contraception are:~* Barrier type devices (e.g., female condom, diaphragm, contraceptive sponge) only in combination with a spermicide.~* Intra-uterine devices.~* Oral, injectable, implantable or transdermal contraceptives only in combination with a barrier method.~  * Abstention, rhythm method, and contraception by the partner alone are not acceptable methods of contraception.~Women not of childbearing potential are defined as prepubescent, postmenopausal (i.e., amenorrhea for at least 1 year), or surgically or naturally sterile.~* Body mass index (BMI) between 18 and 30 kg/m2 (limits included) at screening visit.~* 12-lead ECG without clinically relevant abnormalities at screening visit.~* Hematology and biochemistry test results not deviating from the normal range to a clinically relevant extent at screening visit and following the screening/adaptation night.~* Primary insomnia by DSM-IV-TR criteria based on medical history and the assessments performed at screening visit.~* History of the following for at least 3 months prior to the screening visit:~  * Usual reported subjective total sleep time (TST) 3 - 6 hours.~ * Usual sleep disturbance with a subjective sleep onset latency of \> 30 min.~ * Daytime complaints associated with poor sleep (e.g., fatigue, irritability, difficulty concentrating).~* Polysomnography (PSG) at screening/adaptation night confirming TST \< 6 h and LPS ≥ 20 min.~* Willingness to refrain from CNS-active drugs for 5 half-lives of the respective drug (but at least 1 week) prior to the screening/adaptation night and up to the end of treatment period 2. The usage of short-acting hypnotics (defined as hypnotics with a half-life of up to and including 10 hours) is allowed up to 48 hours prior to each PSG night, i.e., prior to the screening/adaptation night and prior to the treatment PSG nights.~* Urine drug test negative for barbiturates, cannabinoids, amphetamines, and cocaine at screening visit 1, screening/adaptation PSG night and pre-treatment. Urine drug test negative for benzodiazepines and opiates at screening/adaptation PSG night and pre-treatment.~* Signed informed consent prior to any study-mandated procedure.~Exclusion Criteria:~* Symptom assessment questionnaire (SBB) for diagnosis of apnea resulting in a score \> 2 at screening visit.~* Zung self-rating depression scale (SDS) and/or Zung self-rating anxiety scale (SAS) resulting in a raw score ≥ 50 at screening visit.~* Restless legs syndrome and/or meeting all four essential diagnostic criteria for RLS (see Appendix 10).~* Insomnia due to sleep apnea or periodic limb movement disorder as assessed by PSG at screening/adaptation night:~  * apnea/hypopnea index (AHI) \> 10/h~ * periodic limb movement arousal index \> 10/h~* Major depressive disorder, severe psychosis, or significant anxiety disorder.~* Pregnancy or breast-feeding.~* Systolic blood pressure \> 160 mmHg and/or diastolic blood pressure \> 100 mmHg at screening visit.~* Within the 2-month period prior to the screening visit, clinical evidence of alcoholism or drug abuse.~* Any known factor or disease that might interfere with treatment compliance, study conduct or interpretation of the results such as psychiatric disease or a disease which may affect the pharmacokinetics of the study drug.~* Treatment with strong inhibitors of CYP3A4 (e.g., azole derivatives, ritonavir, clarithromycin) within 1 week prior to the screening/adaptation PSG night and up to the end of treatment period 2.~* Excessive caffeine consumption (regular caffeine consumption of \> 7 units per day).~* Night shift workers.~* Known hypersensitivity to any excipients of the drug formulation.~* Planned treatment or treatment with another investigational drug within 1 month prior to randomization and up to the end of treatment period 2.~* Known concomitant life-threatening disease with a life expectancy \< 24 months.~* Unstable medical abnormality, significant medical disorder or acute illness.~* Recruitment of the same patient twice to the same dose level. Patients may be recruited to a lower dose level, provided that there are at least 28 days between last study drug administration and screening/adaptation PSG night.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None
- 3 (Type: EXPERIMENTAL): None
- 4 (Type: EXPERIMENTAL): None
- 5 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).